Faron Pharmaceuticals - Innovative medicinske løsninger (Del 2)

Endnu en nylig oversigtsartikel i et andet toptidsskrift, Cell Press’ Trends in Cancer. Bemærk, at det også her kun er BEXMABs fase 1-publikation, der nåede med. Virksomhedsmeddelelser, forskeres opfattelser og kongrespræsentationer bliver først til reel virkelighed i fagfællebedømte publikationer, hvorfra de, hvis kvaliteten er høj nok, kan finde vej til oversigtsartikler. Det går altså langsomt fremad her også.

Macrophage-directed therapeutic strategies in cancer

Betalingsmur, kan ikke engang åbnes med universitetslogin, men burde kunne via universitetshospitalet. Forfatterne er også selv fra University of California.

https://www.cell.com/trends/cancer/fulltext/S2405-8033(26)00191-3#f0005

Bex nævnes, og Clever betragtes som en nøgleregulator for myeloide celler i cancer. Forfatterne anser BEX’ HR-MDS-resultater for at være klinisk evidens for, at påvirkning af makrofag-interne signalveje kan give terapeutisk gevinst.

Oversigten er adskillige tier sider lang, 289 referencer, hvoraf 1 er Maijas oversigt om påvirkning af makrofager, 1 ekstern artikel om Stabilin-1, 1 MATINS, 1 Kontros BEXMAB og 1 af Maija om Bex’ aktivering af T-celler i cancer.

De skriver:
”CLEVER-1 (also known as Stabilin-1) is another inhibitory receptor that has recently emerged as a key regulator of myeloid cell function in cancer [114]. In preclinical mouse models, anti-CLEVER-1 antibodies have been shown to reprogram TAMs, enhance antitumor immunity, and improve responses to ICB [115]. Based on these findings, anti-CLEVER-1 therapy has advanced to clinical evaluation. Bexmarilimab (IgG4, Faron Pharmaceuticals), a human Fc-silent anti-CLEVER-1 antibody, has demonstrated encouraging clinical activity in patients with high-risk myelodysplastic syndromes [116], providing clinical proof of concept that targeting macrophage-intrinsic pathways can elicit therapeutic benefit. Consistent with these findings, bexmarilimab has shown promising results in patients with cutaneous melanoma, gastric cancer, HCC, estrogen receptor-positive breast cancer, and biliary tract cancer, and has demonstrated good tolerability [117]. Responding patients exhibited bexmarilimab-induced macrophage activation and increased IFN-γ and T-cell receptor signaling compared with nonresponders.”

Clever klassificeres blandt receptorer, der regulerer reprogrammering af makrofager, som en dæmpende faktor:

Heller ikke denne oversigt beviser, at Bex eller nogen anden mekanisme virker klinisk, men den styrker endnu en gang Clever-1/Bex-aksens position i feltet.

12 Synes om